Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
Evaluation of the Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
Chen Ying
782 participants
Jan 25, 2024
INTERVENTIONAL
Conditions
Summary
The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of patients with critical infection, in the hope that the therapy will provide alternatives to the treatment of patients with critical infection.
Eligibility
Inclusion Criteria3
- Age greater than 18 years;
- Meets the diagnostic criteria for sepsis according to the "Sepsis-3" ;
- Patient or their legal representative consents to treatment and signs an informed consent form.
Exclusion Criteria6
- Patients expected to die within 24 hours after enrollment;
- Contraindications to low molecular weight heparin and scopolamine butylbromide drugs;
- Patients with thrombotic diseases requiring treatment with low molecular weight heparin;
- Patients with terminal-stage malignancies, severe immunodeficiency, immunosuppression, severe liver or kidney dysfunction (defined as liver or kidney SOFA score ≥ 3 points), etc.;
- Pregnant and lactating women;
- Patients participating in other clinical trials.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05634057